Eliksa Therapeutics, Inc
- Biotech or pharma, therapeutic R&D
Eliksa Therapeutics is a spinout from the University of Utah developing ELK-003, a first-in-class topical biologic eye drop. Our lead indication targets ocular manifestations associated with all forms of epidermolysis bullosa, a group of rare pediatric genetic diseases affecting approximately 30,000 individuals in the United States, and it's currently being evaluated in a pilot clinical trial. Our second indication for ELK-003 is neurotrophic keratitis, a degenerative corneal disease with limited treatment options, currently in preclinical development.
In addition to our internal programs, we are actively exploring opportunities to in-license additional drug candidates for rare diseases.
Meeting Request Note: Due to time constraints, we will respectfully decline meetings with CDMOs, CROs and other vendors
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}